Develops cretostimogene, an investigational therapy for people with high- and intermediate-risk bladder cancer.
10-K for FY2025, filed Feb 27, 2026We are a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec…View ↗
We are evaluating the safety and efficacy of cretostimogene as a monotherapy in BOND-003 Cohort C, our ongoing Phase 3 clinical trial in…View ↗
We are also conducting a Phase 3 clinical trial, PIVOT-006, the first randomized registrational trial to evaluate an investigational…View ↗
Commercial and development revenue (80% of revenue) comes from manufacturing products supplied to customers. License and collaboration agreements generate upfront payments, development milestones when achieved, and royalties tied to licensed-product sales.
10-K for FY2025, filed Feb 27, 2026The Company recognizes revenue from the commercial and development contracts in accordance with ASC 606. Commercial and development revenue…View ↗
The Company’s performance obligations under the terms of these agreements include a license grant, research and development services or…View ↗
The License and Collaboration Agreements include milestone payments that are triggered by the achievement of development milestones. These…View ↗
The License and Collaboration Agreements also include certain sales-based milestone and royalty payments upon successful commercialization…View ↗
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗$4M
10-K for FY2025, filed Feb 27, 2026
$4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Commercial and Development Revenue
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
80% |
Commercial and Development Revenue, FY2025
$3.2M Sources
|
Sold outright |
|
License and Collaboration Revenue
Licensed
10-K for FY2025, filed Feb 27, 2026 |
20% |
License and Collaboration Revenue, FY2025
$806K Sources
|
Licensed |
Kissei receives a territorial license and purchases its clinical and commercial product supply directly; under supply arrangements, customers typically provide the active ingredient or other proprietary materials used in manufacturing.
10-K for FY2025, filed Feb 27, 2026
No. It lost $161M in FY2025.
10-Q for Q3 FY2026, filed Nov 6, 2026
Open tableView ↗
8-K, filed Apr 13, 2026
On April 13, 2026, CG Oncology, Inc. (the “Company”) appointed Jim DeTore as the Company’s Chief Financial Officer.View ↗
Competes with Bristol Meyers Squibb, enGene, Gilead Sciences, Hoffman-La Roche, ImmunityBio, Johnson & Johnson, Merck, Protara Therapeutics, Pfizer, Relmada Therapeutics, and UroGen Pharma
10-K for FY2025, filed Feb 27, 2026We will continue to face competition from current standard of care treatments, including BCG. To the extent Merck or another manufacturer…View ↗
Loading...